SCHEMBL5772968

SCHEMBL5772968

Cc1c(O)cc2c(-c3ccc(F)cc3)coc2c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 5/20 0.52
ALDH1A1 P00352 2/20 0.45
GSK3B P49841 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
HSD17B10 Q99714 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
PPARG P37231 1/20 0.43
PPARD Q03181 1/20 0.43
PPARA Q07869 1/20 0.43
MAPT P10636 3/20 0.41
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
LMNA P02545 1/20 0.40
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5772347 0.85 POLB (0.50) POLBALDH1A1HSD17B10KDM4EHPGD
SCHEMBL5771774 0.84 ALOX15 (0.47) POLBALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL5768940 0.82 ABCB1 (0.51) POLBALDH1A1GSK3BSMN1; SMN2HSD17B10
SCHEMBL5771402 0.77 ABCB1 (0.46) POLBALDH1A1GSK3BSMN1; SMN2HSD17B10
SCHEMBL5898901 0.75 MAPT (0.47) POLBALDH1A1GSK3BSMN1; SMN2HSD17B10
SCHEMBL5383815 0.67 KDM4E (0.78) POLBALDH1A1GSK3BSMN1; SMN2HSD17B10
SCHEMBL10563010 0.67 ALOX12 (0.78) POLBALDH1A1SMN1; SMN2HSD17B10NPC1
SCHEMBL10558084 0.66 XDH (0.78) ALDH1A1SMN1; SMN2HSD17B10NPC1RAB9A
SCHEMBL11702360 0.66 SMN1; SMN2 (0.41) POLBALDH1A1GSK3BSMN1; SMN2HSD17B10
SCHEMBL21363228 0.64 ALOX15 (0.48) ALDH1A1HSD17B10NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1472241-A4 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS INC (US) 2005-06-29 EP claimed
EP-1472241-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES Galileo Pharmaceuticals, Inc. (US) 2004-11-03 EP claimed
US-6653346-B1 Amtiischemic and antiinflammatory agents GALILEO PHARMACEUTICALS, INC. 2003-11-25 US claimed
WO-2003066618-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS, INC. (US) 2003-08-14 WO claimed
US-7078541-B2 Benzofuran derivatives GALILEO PHARMACEUTICALS, INC. (US) 2006-07-18 US disclosed
EP-1472241-A4 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS INC (US) 2005-06-29 EP disclosed
WO-2005027900-A1 BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed
EP-1472241-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES Galileo Pharmaceuticals, Inc. (US) 2004-11-03 EP disclosed
US-20040063975-A1 Benzofuran derivatives EDISON PHARMACEUTICALS, INC. 2004-04-01 US disclosed
US-6653346-B1 Amtiischemic and antiinflammatory agents GALILEO PHARMACEUTICALS, INC. 2003-11-25 US disclosed
WO-2003066618-A1 CYTOPROTECTIVE BENZOFURAN DERIVATIVES GALILEO PHARMACEUTICALS, INC. (US) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063975-A1 Benzofuran derivatives NDUFAB1, AIFM1, NDUFAF1 POLB 1299/4885ALDH1A1 404/4885GSK3B 2296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.